Evidence map›Paper›PMID 42443515›Full record

ArticleNature medicine2026

An anti-PMEL antibody-drug conjugate with a G

Matteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, Ryan J Sullivan, Richard Carvajal, Reinhard Dummer, Tanja Gromke, Jessica C Hassel, Damien Kee, Egle Ramelyte and 22 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Matteo S CarlinoWestmead and Blacktown Hospitals, University of Sydney, Sydney, New South Wales, Australia. matteo.carlino@sydney.edu.au.ORCID http://orcid.org/0000-0002-7861-4104
Ellen KapiteijnLeiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-4814-6426
Sophie Piperno-NeumannInstitut Curie, Paris, PSL Research University, Paris, France.
Ryan J SullivanMassachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Richard CarvajalNorthwell Health Cancer Institute, Lake Success, NY, USA.
Reinhard DummerUniversity Hospital Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-2279-6906
Tanja GromkeUniversity Hospital Essen, Essen, Germany.
Jessica C HasselHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
Damien KeePeter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-4685-1666
Egle RamelyteUniversity Hospital Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-8262-8608
Alexander N ShoushtariMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8065-4412
Alexander Z WeiColumbia University Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0003-3290-9959
Alexander EnkHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1816-421X
Eleanor E HandelWestmead and Blacktown Hospitals, University of Sydney, Sydney, New South Wales, Australia.
Kamaneh MontazeriMassachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3693-5994
Jorge Ramon-PatinoSTART Madrid-CIOCC, Centro Integral Oncologico Clara Campal, Madrid, Spain.
Heike RichlyUniversity Hospital Essen, Essen, Germany.
Manuel RodriguesInstitut Curie, Paris, PSL Research University, Paris, France.ORCID http://orcid.org/0000-0002-5443-0802
Shahneen SandhuPeter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8660-4475
James SmithyMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3126-1193
Frank M SpeetjensLeiden University Medical Center, Leiden, The Netherlands.
Pedro Milanez-AlmeidaBiomedical Research, Novartis, Cambridge, MA, USA.
Anwesha ChaudhuryDevelopment, Novartis, Cambridge, MA, USA.
Keith HoffmasterBiomedical Research, Novartis, Cambridge, MA, USA.
Mary IsingBiomedical Research, Novartis, East Hanover, NJ, USA.
Javier A OteroBiomedical Research, Novartis, East Hanover, NJ, USA.
Thiruvamoor RamKumarBiomedical Research, Novartis, East Hanover, NJ, USA.
Aimee ReynoldsBiomedical Research, Novartis, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4703-6388
Sherif SharabyBiomedical Research, Novartis, East Hanover, NJ, USA.ORCID http://orcid.org/0009-0003-6259-4369
Lillian WernerDevelopment, Novartis, Cambridge, MA, USA.
Padmaja Yerramilli-RaoBiomedical Research, Novartis, Cambridge, MA, USA.
Emiliano CalvoSTART Madrid-CIOCC, Centro Integral Oncologico Clara Campal, Madrid, Spain.ORCID http://orcid.org/0000-0003-4921-829X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748Novartis Pharmaceuticals Corporation (NPC) NA
6 · The paper itself

Abstract

Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85-90% of tumors harbor activating GNAQ and GNA11 mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody-drug conjugate, binds surface PMEL and delivers the potent Gα

Indexed as

GTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11ImmunoconjugatesMelanomaUveal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedMutationUveal MelanomaGNA11 protein, humanGNAQ protein, humanGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11Immunoconjugates

Identifiers

PMID42443515
PMCPMC13577922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.